When a 63-year-old man enrolled in a clinical trial with 14 cancerous lesions in his liver, he had already been through multiple lines of treatment. His prostate cancer was castration-resistant — the most advanced and hardest-to-treat form. He was running out of options.
After six cycles of VIR-5500, all 14 lesions were gone.
That case is not an outlier in the data. It is illustrative of a pattern that has sent a ripple of excitement through oncology — the early results of a drug that works in a fundamentally different way from anything that came before it.
**The 'Invisibility Cloak': How VIR-5500 Works**
Prostate cancer cells carry on their surface a protein called PSMA — prostate-specific membrane antigen. VIR-5500 is a **dual-masked T-cell engager**: it is engineered to bind both to the body's T-cells (the immune system's cancer-fighting soldiers) and to PSMA on prostate cancer cells, forcing them into direct, lethal contact.
But the truly novel element is what Vir Biotechnology calls the **'cloaking device.'**
Earlier T-cell engagers had a serious problem: they activated the immune system systemically, causing widespread inflammation, fever, and dangerous side effects wherever they went. VIR-5500 is designed to stay masked — effectively invisible — while circulating in the bloodstream, only becoming active when it reaches the tumour environment.
The result is a drug that can remain in the bloodstream longer, potentially require fewer doses, and cause dramatically fewer side effects than older approaches.
**The Numbers**
Presented at the **2026 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium** on February 26, the Phase 1 trial data covers 58 patients with advanced metastatic castration-resistant prostate cancer (mCRPC) — a group who had progressed through multiple prior lines of therapy.
At the highest dose cohorts, the results were striking:
- **82%** of PSA-evaluable patients experienced at least a 50% decline in PSA (the key cancer biomarker) - **53%** experienced at least a 90% PSA decline - **45% objective response rate** — tumors measurably shrinking on imaging - **Grade ≥3 side effects in just 12% of patients** — far lower than comparable therapies - No dose-limiting toxicities observed
Cytokine release syndrome — the dangerous immune overreaction that plagued earlier T-cell engagers — was observed in 50% of patients, but was almost entirely Grade 1 (fever only). No routine steroids required.
*'These are remarkable results for a patient population that has already exhausted multiple treatment lines. The safety profile is particularly impressive given the mechanism of action.'* — Institute of Cancer Research, London
**A Partnership Worth $1.37 Billion**
The data was strong enough that pharmaceutical giant **Astellas** moved fast. On February 24, 2026 — two days before the ASCO presentation — Astellas and Vir Biotechnology announced a **global strategic collaboration** to advance VIR-5500. Vir is eligible for up to **$1.37 billion in milestones** plus royalties on ex-US net sales.
Monotherapy dose-escalation is complete. **Combination trials and Phase 3 pivotal trials are planned for 2027.** Expansion cohorts begin Q2 2026.
**Why This Matters for 1.5 Million Men**
Prostate cancer is the second most common cancer in men worldwide. Metastatic castration-resistant prostate cancer — the form where standard hormone therapy no longer works — carries a five-year survival rate below 30%. For patients in that situation, a drug that can produce 45% objective response rates with a manageable safety profile represents something genuinely new.
The single case — 14 liver lesions, all gone after six cycles — is not the story. It is an illustration of what the aggregate data suggests is possible.
Phase 3 can't come soon enough. 💙
*Sources: Vir Biotechnology (ASCO GU 2026, February 26, 2026) · The Guardian · Institute of Cancer Research, London · UroToday · Astellas press release*